Daniel S. Lynch
Executive Chairman and Interim CEO of Surface Onco
novel cancer treatment ERBITUX.
Universidade Federal de Santa Catarina
Norway
Biography
Daniel S. Lynch is the Executive Chairman and Interim CEO of Surface Oncology, and a strategic advisor at Third Rock Ventures. He brings more than 25 years of experience in biotechnology and pharmaceutical companies, and has active board roles in several companies including Chairman at bluebird bio, Blueprint Medicines, and Rana Therapeutics. Mr. Lynch served as Chief Executive and Chief Financial Officer of ImClone Systems Corp.
Research Interest
biotechnology
